RFL — Rafael Holdings, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1713863 ·
Last close
$0.91
Market Cap
$46.95M
52W High
$3.96
52W Low
$0.89
ADV30
64,931
Next earnings
2026-12-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 244,000 | 231,000 | -9,731,000 | -9,176,000 | 83,055,000 | 22,074,000 | 11,085,000 |
| Apr 2026 | 179,000 | 171,000 | -6,870,000 | -4,226,000 | 91,990,000 | 30,497,000 | 11,187,000 |
| Jan 2026 | 211,000 | 199,000 | -6,655,000 | -6,417,000 | 99,315,000 | 37,779,000 | 16,057,000 |
| Oct 2025 | 240,000 | 231,000 | -10,141,000 | -9,816,000 | 105,375,000 | 45,539,000 | 16,195,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,987,000
Investing CF
$-676,000
Financing CF
$-116,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.59
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-261,898,000
Inventory
$377,000
Receivables
$444,000
ST Investments
$0
EBIT TTM
$-27,622,000
Pretax Income TTM
$-27,955,000
Interest Exp TTM
$333,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$874,000
EBITDA
$-33,205,000
Free Cash Flow
$-20,674,000
Enterprise Value
$40,551,876
Total Cash
$22,074,000
Total Debt
$610,000
Shares Out
51,397,436
Trailing EPS
$-0.58
Book Value
$1.27
ROE
-32.8%
ROA
-21.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jul 2026 | 874,000 | -33,409,000 | -29,635,000 | 83,055,000 | 11,085,000 | 66,309,000 | -29,987,000 |
| Jul 2025 | — | — | — | — | — | — | — |
| Jul 2024 | 637,000 | -102,627,000 | -34,410,000 | 96,832,000 | 10,574,000 | 82,185,000 | -7,802,000 |
| Jul 2023 | 279,000 | -15,043,000 | -1,876,000 | 98,829,000 | 2,200,000 | 100,293,000 | -10,886,000 |
| Jul 2022 | 410,000 | -60,477,000 | -124,658,000 | 118,320,000 | 21,114,000 | 100,515,000 | -26,079,000 |
TTM Snapshot
Revenues TTM
$980,000
NetIncome TTM
$-32,553,000
OpCashFlow TTM
—
Assets (Latest)
$91,990,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLNN | Clene Inc. | $46.37M | $3.22 | — |
| SMNR | Semnur Pharmaceuticals, Inc. | $46.04M | $0.20 | — |
| NMAD | NOMAD POWER SOLUTIONS, INC. | $48.30M | $3.00 | — |
| APLM | Apollomics Inc. | $49.09M | $16.84 | — |
| PDSB | PDS Biotechnology Corp | $50.03M | $0.89 | — |
News headlines (Yahoo Finance, 1h cache)
Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-03 16:14 · Yahoo
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
2026-10-29 12:00 · Yahoo
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
2026-10-29 11:00 · Yahoo
Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
2026-10-04 06:01 · Yahoo
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
2026-10-01 13:49 · Yahoo
Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint
2026-09-30 13:49 · Yahoo
Rafael Holdings stock tumbles 25% as drug trial misses goal
2026-09-30 13:47 · Yahoo
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
2026-09-30 11:00 · Yahoo
Rafael Holdings Insider Ups Holding By 1,810% During Year
2026-04-28 14:26 · Yahoo
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
2026-06-11 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.